Bausch Health Companies Inc. Payments to Acquire Short-term Investments
Bausch Health Companies Inc. (BHC) reported Payments to Acquire Short-term Investments of $0 for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-10-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2014-10-24
- Bausch Health Companies Inc. payments to acquire short-term investments for the quarter ending 2014-09-30 was $0.00.
- Bausch Health Companies Inc. payments to acquire short-term investments for the quarter ending 2014-06-30 was $75.90M.
- Bausch Health Companies Inc. payments to acquire short-term investments for the quarter ending 2013-12-31 was $0.00.
- Bausch Health Companies Inc. payments to acquire short-term investments for the quarter ending 2013-09-30 was $0.00.
- Bausch Health Companies Inc. payments to acquire short-term investments for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Bausch Health Companies Inc. payments to acquire short-term investments for fiscal 2012 was $7.20M, a 91.12% decline from fiscal 2011.
- Bausch Health Companies Inc. payments to acquire short-term investments for fiscal 2011 was $81.09M.
- Bausch Health Companies Inc. payments to acquire short-term investments for fiscal 2009 was $3.82M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2014-09-30 | $0.00 10-Q · filed 2014-10-24 | $75.90M derived: sum of 2 quarters · filed 2014-10-24 | $75.90M 10-Q · filed 2014-10-24 | |
| 2014-06-30 | $75.90M 10-Q · filed 2014-08-01 | $75.90M 10-Q · filed 2014-08-01 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-10-24 | $0.00 derived: sum of 3 quarters · filed 2014-10-24 | $0.00 10-K · filed 2014-02-28 |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-24 | $0.00 derived: sum of 2 quarters · filed 2014-10-24 | $0.00 10-Q · filed 2014-10-24 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-01 | $0.00 10-Q · filed 2014-08-01 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $0.00 derived: sum of 3 quarters · filed 2014-02-28 | $7.20M 10-K · filed 2014-02-28 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-01 | $0.00 derived: sum of 2 quarters · filed 2013-11-01 | $7.20M 10-Q · filed 2013-11-01 | $7.20M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-06-30 | $0.00 10-Q · filed 2013-08-07 | $7.20M 10-Q · filed 2013-08-07 | $7.20M derived: sum of 3 quarters · filed 2014-02-28 | $18.95M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-03-31 | $7.20M 10-Q · filed 2013-05-03 | $7.20M derived: sum of 2 quarters · filed 2014-02-28 | $18.95M derived: sum of 3 quarters · filed 2014-02-28 | $48.27M derived: sum of 4 quarters · filed 2014-02-28 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $11.74M derived: sum of 2 quarters · filed 2014-02-28 | $41.07M derived: sum of 3 quarters · filed 2014-02-28 | $81.09M 10-K · filed 2014-02-28 |
| 2011-09-30 | $11.74M 10-Q · filed 2012-11-05 | $41.07M derived: sum of 2 quarters · filed 2012-11-05 | $81.09M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $29.33M 10-Q · filed 2012-08-03 | $69.34M 10-Q · filed 2012-08-03 | ||
| 2011-03-31 | $40.02M 10-Q · filed 2012-05-04 | |||
| 2009-12-31 | $3.82M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |